VTV250516P179000
- 0.00
- 0.000.00%
Vanguard Value ETF Newsroom
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Amazon Sellers Hike Prices On Essentials As Trump China Tariffs Squeeze Margins
Procter & Gamble Analysts Lower Their Forecasts Following Q3 Results
Check Out What Whales Are Doing With UNH
UnitedHealth Group Shares Are Trading Lower After Barclays Cut Its Price Target on the Stock From $560 to $513.
Citigroup Maintains Buy on Procter & Gamble, Lowers Price Target to $181
4 Stocks to Watch on Friday: GILD, ABBV, CL and SLB
Procter & Gamble Analyst Ratings
AbbVie Spikes as Q1 Beat Prompts Guidance Raise
AbbVie Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Adjusted EPS Guidance.
Earnings Snapshot: AbbVie Tops Q1 Estimates Even as Humira Sales Lag, Profit Outlook Beats
AbbVie Non-GAAP EPS of $2.46 Beats by $0.06, Revenue of $13.34B Beats by $420M
Earnings Scheduled For April 25, 2025
The economic uncertainty is too great, and Americans are afraid to buy houses now.
High interest rates continue to stifle market demand, coupled with tariffs increasing economic uncertainty, leading to a collapse in USA home sales in March, reaching the worst level since the financial crisis.
The company's CEO has clearly stated: the trade war will destroy everything!
Due to the cost surge brought about by Trump's tariff policy and the wavering of Consumer confidence, many corporate giants in the USA have significantly lowered their earnings expectations during this earnings report season, covering various fields such as Consumer goods, Aviation, Energy, and telecommunications. Statistics show that more than 90% of companies mentioned the impact of tariffs during their earnings call, with the mention rate of the term 'recession' soaring from less than 3% in the fourth quarter of last year to 44%.
US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher
Trump's 'tariff stick' is useless? USA consumer giant Procter & Gamble: Will still source from China!
① Procter & Gamble is finding it difficult to shift procurement operations from China due to Trump's tariffs, expecting an annual cost increase of 1 billion to 1.5 billion USD, and can only cope by raising prices; ② Procter & Gamble has lowered its annual revenue forecast, anticipating that USA consumers will cut spending due to economic uncertainty, and total net sales for 2025 will remain flat compared to last year.
Exxon Wins Critical Lithium Rights in Arkansas, Gaining Edge Over Occidental in Regulatory Battle
Here's the Major Earnings Before the Open Tomorrow
SCHD Is Down, But Its Dividend Is Up And These 2 ETFs Are Quietly Catching Up